Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta
about
Peroxisome proliferator-activated receptors (PPARs) and ovarian function--implications for regulating steroidogenesis, differentiation, and tissue remodeling.Intramyocellular lipid kinetics and insulin resistanceThe Role of PPARs in CancerSXR, a novel steroid and xenobiotic-sensing nuclear receptorExpression of PEX11beta mediates peroxisome proliferation in the absence of extracellular stimuliCloning, expression, and fatty acid regulation of the human delta-5 desaturaseProstacyclin-dependent apoptosis mediated by PPAR deltaThe peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling.Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription.PPARdelta regulates glucose metabolism and insulin sensitivityPPAR delta: a dagger in the heart of the metabolic syndrome.Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasisNatural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a reviewPeroxisome proliferator-activated receptor alpha mediates the adaptive response to fastingIntegrated physiology and systems biology of PPARαA selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transportFatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha - and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleusPPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1PPARs and the cardiovascular systemIdentification of a human nuclear receptor defines a new signaling pathway for CYP3A inductionOrphan nuclear receptors in drug discoveryIdentification of a physiologically relevant endogenous ligand for PPARalpha in liverThe orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolismIn vitro and in vivo evidence for orphan nuclear receptor RORalpha function in bone metabolismInduction of Tissue Factor Expression in Endothelial Cells by Basic Fibroblast Growth Factor and its Modulation by Fenofibric acidRole of Peroxisome Proliferator-Activated Receptors in Inflammation ControlRelationship between PPARalpha activation and NO on proximal tubular Na+ transport in the ratA general introduction to the biochemistry of mitochondrial fatty acid β-oxidationPeroxisome Proliferator-Activated Receptors in Female Reproduction and FertilityThe Deep Correlation between Energy Metabolism and Reproduction: A View on the Effects of Nutrition for Women FertilityZebrafish as a Model to Study the Role of Peroxisome Proliferating-Activated Receptors in Adipogenesis and ObesityPhospholipid--driven gene regulationOrphan nuclear receptors and the regulation of nutrient metabolism: understanding obesityNuclear hormone receptor functions in keratinocyte and melanocyte homeostasis, epidermal carcinogenesis and melanomagenesisThe case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathyTranscriptional regulation of fibroblast growth factor 21 expressionMegalin/LRP2 expression is induced by peroxisome proliferator-activated receptor -alpha and -gamma: implications for PPARs' roles in renal functionPPARδ activation acts cooperatively with 3-phosphoinositide-dependent protein kinase-1 to enhance mammary tumorigenesisSulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacyStructural Basis for Iloprost as a Dual Peroxisome Proliferator-activated Receptor / Agonist
P2860
Q21245560-8F7E0E18-9A18-4395-A957-8B10AAC3D19CQ21245684-3EC06DA7-DA99-4E94-81E6-3CE5D573F800Q21342955-4505CDA3-8EE4-46CE-ADD1-4424367009C1Q22003995-E3B626B7-4620-4DB7-B30F-BDE3E435F8B4Q22004167-E1CA14F4-762D-44CD-9532-D7387AF80129Q22010939-70E61A6E-402E-479C-AB8A-19A6D1D5B9DBQ24291677-F4A4C7CD-C089-4136-9B90-74BBDDC4D379Q24530668-EBDE18F1-563E-4D9C-8DDB-BAAD469E6C49Q24540092-C7708E3D-5F86-423C-9EF9-9E5215517DDDQ24541495-EDB9A42E-F2B9-4669-9C9A-DF3EBC3A9DADQ24541527-9EB3F770-6569-4536-8B48-481369D7E190Q24541529-30CE88A3-8182-43C3-8886-1CF739D85C7DQ24561401-7FB46D03-CB53-47AF-B2AB-F2DAF4C6CF4EQ24563197-6A4C5D94-10E5-40F7-BABF-540D3B75BAF3Q24564130-CA990EC6-38BD-49EB-99ED-A3A329753110Q24603087-07F2684A-4875-48EF-8FB2-0C84D57E621EQ24612974-F77D8FB3-69FD-4445-8986-C6039E81C535Q24633440-74FC615C-1207-42F2-AC7A-480D1E005CD4Q24642728-2BB230CF-74E2-49DE-AD2B-86B99FBFB278Q24646162-7ECE841C-3969-49D4-B8D5-2BAC483EBB90Q24649596-48DC5862-FCC5-44DC-80FE-D964CEF6BD0BQ24653691-3FF31711-AF3B-419A-B28A-57D18963D6C0Q24657371-289510D1-1EB1-4973-8236-D90091B00534Q24675720-B3B76AC4-16CB-4B71-ACB7-DC4FC65FFFEBQ24793878-0CF168C5-C217-44A9-AD3B-0D5159DB63C9Q24796541-2A7056BB-12BA-4F3F-A0C9-B8E74CEA6F27Q24799696-71C9D678-F777-4BC2-9E94-A9086BB2C0F9Q26699142-82D20B0E-5763-49B0-961D-E64710C16728Q26738962-A30D4367-DCC2-466C-9785-9D0FA67484BBQ26766160-2FD279A9-CEFE-4913-946D-CE5818D41DB0Q26772316-89D68FB4-5AB1-46AB-8D2D-39E832848EF5Q26822791-5D602903-C8CE-4F34-B222-BF6104EBCCADQ26823819-8D9C6425-B76A-433A-A61E-A7F5CB5040AEQ26859617-E0EB2471-75F0-4EE6-81B0-98B4095FCA74Q26865958-3249C8D4-1EFC-4476-B862-838C0548FC07Q27024818-C148FAF0-ADCE-4F95-9F2E-6AB3308130E4Q27437610-40B84492-C372-48B2-A8D4-2DC2E22AE485Q27437643-309F0044-BFE2-412C-B637-B737411CCBE7Q27666968-12DD12A8-C26C-4B87-916C-29346BAEEE4AQ27670895-18A28574-D870-4D7F-B165-710BA337F10A
P2860
Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta
description
1997 nî lūn-bûn
@nan
1997 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Hypolipidemic drugs, polyunsat ...... ated receptors alpha and delta
@ast
Hypolipidemic drugs, polyunsat ...... ated receptors alpha and delta
@en
Hypolipidemic drugs, polyunsat ...... ated receptors alpha and delta
@nl
type
label
Hypolipidemic drugs, polyunsat ...... ated receptors alpha and delta
@ast
Hypolipidemic drugs, polyunsat ...... ated receptors alpha and delta
@en
Hypolipidemic drugs, polyunsat ...... ated receptors alpha and delta
@nl
prefLabel
Hypolipidemic drugs, polyunsat ...... ated receptors alpha and delta
@ast
Hypolipidemic drugs, polyunsat ...... ated receptors alpha and delta
@en
Hypolipidemic drugs, polyunsat ...... ated receptors alpha and delta
@nl
P2860
P3181
P356
P1476
Hypolipidemic drugs, polyunsat ...... ated receptors alpha and delta
@en
P2093
P2860
P304
P3181
P356
10.1073/PNAS.94.9.4312
P407
P577
1997-04-01T00:00:00Z